Medicinal cannabis company AusCann Group Holdings confirms that Ido Kanyon has commenced today (May 22) as the company’s Chief Executive Officer (CEO).
Mr Kanyon’s appointment was announced in February following a comprehensive international executive search conducted by the AusCann Board, with a scheduled start date of 22 May 2019.
Mr Kanyon is a highly experienced global pharmaceutical executive with more than 15 years of pharmaceutical and medical device business experience across the life-science value chain. He has successfully launched innovative medicines globally, providing more patients with access to cost-effective, high-quality, life-changing treatment options. His experience covers a comprehensive range of healthcare technologies and commercial strategies: from capsules and inhalers to innovative biologics and digital health solutions, the board said in a statement.
AusCann CEO Ido Kanyon said: “I am excited to have formally joined the team at AusCann. I see tremendous opportunity for AusCann to lead in the delivery of cannabis based pharmaceutical solutions that are endorsed by physicians and address the needs of patients who are suffering from inadequately treated medical conditions.
“The company has built a strong platform on which we will continue to grow. We have begun a comprehensive review of our strategic priorities that will help us tailor our operating plans to ensure we deliver the positive healthcare outcomes and shareholder returns we are seeking.”
Mr Kanyon will soon relocate to Perth from the United States, and with Mr Kanyon’s commencement, Interim CEO, Dr Paul MacLeman, will now revert back to his role as an Executive Director of the company.
